Efficacy and safety of GLP-1 receptor agonists and multi-target analogs on body weight and cardiometabolic parameters in non-diabetic individuals with obesity: A systematic review and meta-analysis
10.3760/cma.j.cn311282-20250505-00236
- VernacularTitle:GLP-1受体激动剂及多靶点类似物对非糖尿病肥胖人群体重及心血管代谢指标影响的 meta分析
- Author:
Shihua HAN
1
;
Lingyong ZENG
;
Xiaopeng LI
;
Jiabao WU
;
Jiale ZENG
;
Zhibin XU
;
Songhao HU
;
Cunchuan WANG
Author Information
1. 广东药科大学东莞清溪医院内分泌科，东莞 523660
- Publication Type:Journal Article
- Keywords:
Obesity;
Non-diabetes;
GLP-1 receptor agonist;
Blood pressure;
Lipids;
Adverse events
- From:
Chinese Journal of Endocrinology and Metabolism
2025;41(8):634-642
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aimed to systematically evaluate the efficacy of glucagon-like peptide-1(GLP-1) receptor agonists and multi-target analogs on weight reduction and cardiometabolic outcomes in non-diabetic individuals with obesity, and to compare the efficacy and safety across different GLP-1 receptor agonists.Methods:Randomized controlled trials(RCTs) published between January 2000 and March 2025 were identified through a systematic search of CNKI, Wanfang, Web of Science, PubMed, and Cochrane databases. Two reviewers independently screened the studies, extracted data, and assessed methodological quality. Meta-analysis was performed using RevMan 5.4.1 software. Results:A total of 16 RCTs involving 11 032 non-diabetic individuals with obesity were included. Meta-analysis showed that GLP-1 receptor agonists significantly reduced body weight(ΔWeight=-8.71 kg, 95% CI -10.68 to -6.74, P<0.001) and BMI(ΔBMI=-3.01 kg/m 2, 95% CI -3.77 to -2.25, P<0.001), as well as improved systolic blood pressure(ΔSBP=-4.13 mmHg, 1 mmHg=0.133 kPa, 95% CI -4.87 to -3.39, I2=60%) and diastolic blood pressure(ΔDBP=-1.39 mmHg, 95% CI -2.32 to -0.46, I2=95%). Tirzepatide showed the most pronounced effects on both weight and blood pressure reduction. In addition, GLP-1 receptor agonists significantly lowered LDL-C, TC, and TG, while moderately increasing HDL-C levels. In terms of safety, GLP-1 receptor agonists were associated with an increased risk of gastrointestinal adverse events, but did not significantly increase the risk of hypoglycemia. Conclusion:GLP-1 receptor agonists are effective in reducing weight, BMI, and blood pressure, and in improving lipid profiles in non-diabetic individuals with obesity. However, gastrointestinal side effects should be closely monitored. Given the variability in efficacy and safety among various GLP-1 receptor agonists, personalized treatment approaches are recommended.
